Improved diagnosis of well‐differentiated hepatocellular carcinoma with gadolinium ethoxybenzyl diethylene triamine pentaacetic acid‐enhanced magnetic resonance imaging and Sonazoid contrast‐enhanced ultrasonography
Natsuko Kawada(Osaka International Cancer Institute), Kazuhiro Katayama, Chie Tamai(Osaka International Cancer Institute), Tatsuya Ioka(National Cancer Center Hospital East), Rena Takakura, Sachiko Tanaka(Osaka International Cancer Institute), Yasuna Takano, Kazuyoshi Ohkawa(Osaka International Cancer Institute), Y. Tomita, Takashi Matsunaga(Shiga University of Medical Science), Kazuho Imanaka(Osaka International Cancer Institute), Katsuyuki Nakanishi(The University of Osaka), Tsukasa Kawaguchi(Osaka International Cancer Institute), Hiroyuki Uehara(Osaka International Cancer Institute)
Cited by 43
Related Papers
Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study
|Journal of Clinical Oncology|2013|632
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma
|European Journal of Cancer|2011|573
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
|The Lancet Oncology|2011|396